Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

The Prevalence and Causes of Non-adherence to Immunosuppressive Medications in Patients with Lupus Nephritis Flares

Author(s): Ahmed Yamany Ali*, Tarek Samy Abdelaziz and Mervat Essam Behiry

Volume 16, Issue 3, 2020

Page: [245 - 248] Pages: 4

DOI: 10.2174/1573397115666190626111847

Price: $65

Abstract

Background: Lupus nephritis is one of the major manifestations of SLE. Poor adherence to medications is an important cause of not achieving treatment targets.

Methods: We assessed patients’ adherence to immune-suppressive medications in patients with Lupus nephritis using the Morisky, Green, and Levine (MGL) Adherence Scale. The aim was to study the effect of non-adherence on the occurrence of renal flares.

Results: We recruited 104 patients with lupus nephritis. Sixty-six patients had flares of LN. There was a high prevalence of non-adherence to medications (n=68). Patients who were non-adherent to treatment had more renal flares (p= 0.02). Duration of lupus since diagnosis was significantly higher in patients who had renal flares. Using regression analysis, non-adherence to medications was associated with 3.7 higher risk of developing a single renal flare and 4.9 higher risk of developing more than one renal flare. Causes of non-adherence were medications side effects in 43% of patients, financial issues in 31% or forgetfulness in 26%.

Conclusion: Non-adherence to immunosuppressive medications has a high prevalence in patients with lupus nephritis and is correlated with the number of renal flares.

Keywords: Lupus nephritis, systemic lupus erythromatosus, medication, adherence, immunosuppression, renal flares.

« Previous Next »
Graphical Abstract

[1]
Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol 2012; 2012604892
[http://dx.doi.org/10.1155/2012/604892] [PMID: 22690240]
[2]
Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. CLIN J AM SOC NEPHROL 2017; American Society of Nephrology. 12(5): 825-35.
[http://dx.doi.org/10.2215/CJN.05780616]
[3]
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. N Engl J Med 2011 11/17 2018/12; 365(20): 1886-95.
[4]
Sprangers B, Monahan M, Appel GB. Diagnosis and treatment of lupus nephritis flares—an update. Nature Reviews Nephrology 2012 11/13; 8: 709.
[5]
Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350(10): 971-80.
[http://dx.doi.org/10.1056/NEJMoa031855] [PMID: 14999109]
[6]
Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1(5): 925-32.
[http://dx.doi.org/10.2215/CJN.02271205] [PMID: 17699309]
[7]
Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57(1): 258-64.
[http://dx.doi.org/10.1046/j.1523-1755.2000.00832.x] [PMID: 10620207]
[8]
Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46(4): 995-1002.
[http://dx.doi.org/10.1002/art.10142] [PMID: 11953977]
[9]
Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18(3): 257-63.
[http://dx.doi.org/10.1177/0961203308100481] [PMID: 19213865]
[10]
Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2015; 67(12): 1712-21.
[http://dx.doi.org/10.1002/acr.22636] [PMID: 26097166]
[11]
Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 2000; 13(6): 406-8.
[http://dx.doi.org/10.1002/1529-0131(200012)13:6<406:AID-ART11>3.0.CO;2-2] [PMID: 14635317]
[12]
Lam WY, Fresco P. Medication Adherence Measures: An Overview. BioMed Res Int 2015.2015217047
[http://dx.doi.org/10.1155/2015/217047] [PMID: 26539470]
[13]
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67-74.
[http://dx.doi.org/10.1097/00005650-198601000-00007] [PMID: 3945130]
[14]
Chambers SA, Rahman A, Isenberg DA. Diagnosis and treatment of lupus nephritis flares—an update Nature Reviews Nephrology 2012 11/13; 8: 709.
[http://dx.doi.org/10.1093/rheumatology/kem016]
[15]
Barriers and facilitators to medication adherence: a qualitative study with general practitioners. BMJ Open 2018 01/01; 8(1): e015332.
[16]
El Hadidi KT, Medhat BM, Abdel Baki NM, et al. Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. Lupus 2018; 27(6): 1030-8.
[http://dx.doi.org/10.1177/0961203317751856] [PMID: 29431056]
[17]
Uthman I, Nasr F, Kassak K, Masri A. Systemic lupus erythematosus in Lebanon. Lupus 1999 11/01 2018/12; 8(9): 713-5.
[http://dx.doi.org/10.1191/096120399678841016]
[18]
Khanfir MS, Houman MH, Cherif E, et al. TULUP (TUnisian LUPus): a multicentric study of systemic lupus erythematosus in Tunisia. Int J Rheum Dis 2013; 16(5): 539-46.
[http://dx.doi.org/10.1111/1756-185X.12152] [PMID: 24164841]
[19]
Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991; 91(4): 345-53.
[http://dx.doi.org/10.1016/0002-9343(91)90151-M] [PMID: 1951378]
[20]
Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 2006; 45(9): 1144-7.
[http://dx.doi.org/10.1093/rheumatology/kel039] [PMID: 16527882]
[21]
Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum 2002; 47(6): 630-8.
[http://dx.doi.org/10.1002/art.10790] [PMID: 12522837]

Rights & Permissions Print Cite
Article Metrics
29
© 2025 Bentham Science Publishers | Privacy Policy